Nedaplatin

Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.

Nedaplatin

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	IV
ATC code	none
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name Diammine[(hydroxy-κO)acetato(2-)-κO]platinum
CAS Number	95734-82-0^Y
PubChem CID	9796440
ChemSpider	7972206
UNII	8UQ3W6JXAN
KEGG	D01416^Y
CompTox Dashboard (EPA)	DTXSID8046878
Chemical and physical data
Formula	C2H8N2O3Pt
Molar mass	303.181 g·mol^−1
3D model (JSmol)	Interactive image coordination form: Interactive image
SMILES C(C(=O)[O-])[O-].N.N.[Pt+2] coordination form: O=C1O[Pt-2]([NH3+])([NH3+])OC1
InChI InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1 Key:GYAVMUDJCHAASE-UHFFFAOYSA-M
(verify)

Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.[2]

References

1. Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219-33. doi:10.1530/ERC-15-0237. PMID 26113607.
2. Johnstone TC, Park GY, Lippard SJ (January 2014). "Understanding and improving platinum anticancer drugs--phenanthriplatin". Anticancer Research. 34 (1): 471–6. PMC 3937549. PMID 24403503.

External links

• "Aqupla アクプラ" (PDF). Shionogi & Co. March 2007. Archived from the original (PDF) on 2004-08-05.
• "Official Shionogi & Co. Website" (in Japanese).